ReviewCureus2025
Exploring the Platelet-to-Lymphocyte Ratio for Risk Stratification in Heart Failure: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) remains a global health challenge with high morbidity and mortality, necessitating reliable biomarkers for risk stratification. The platelet-to-lymphocyte ratio (PLR), an emerging inflammatory marker, has shown prognostic potential in cardiovascular diseases, but its utility in HF remains inconsistently reported. This systematic review synthesizes evidence on PLR's prognostic value in HF, focusing on mortality, hospitalization, and its role in multimarker models. We searched four databases -PubMed, Scopus, Web of Science, and Cochrane Library - for English-language observational studies published between January 2020 and June 2025, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Fourteen studies (n=14) were included after screening 172 records. Inclusion criteria comprised adult HF patients with PLR assessed as a prognostic factor; exclusions included reviews, editorials, abstracts without full data, animal studies, and non-English publications. Data on study characteristics, PLR cut-offs, outcomes, effect estimates, and adjustment covariates were extracted. Risk of bias was assessed using the Newcastle-Ottawa Scale. A meta-analysis was not performed due to high heterogeneity in study design, PLR measurement methods, and outcome definitions. Heterogeneity was further evaluated narratively based on methodological inconsistencies, differences in population characteristics, and statistical adjustments. Elevated PLR was significantly associated with increased mortality in ICU and acute HF settings, particularly when combined with the neutrophil-to-lymphocyte ratio (NLR), suggesting additive prognostic value in multimarker models. In contrast, PLR showed limited predictive utility in stable or community-dwelling HF cohorts. Risk of bias findings influenced interpretation, with stronger associations observed in studies with low bias scores. PLR cut-off thresholds varied substantially across studies, affecting comparability. While PLR adds incremental value in acute settings, especially when integrated with other inflammatory markers, its standalone use in chronic HF remains uncertain. Standardization of PLR measurement and further prospective research are essential to clarify its pathophysiological role and clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.